The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.įor more information, please visit Cautionary Statement Regarding Forward-Looking Statements: as a general wellness product as part of its BEAT ®diabetes program. proBEAT ™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT ® to the U.S. sugarBEAT ®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. The company is currently commercializing sugarBEAT ® and proBEAT ™. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. We look forward to discussing further distribution of the proBEAT ™ monitor and associated programs as we progress our commercial initiatives.”įor additional information access the program website at About Nemaura Medical, Inc. The sensor technology provides us with a unique position in this market, at a competitive price point. We have initially adopted a business-to-business model and are actively exploring a range of options for broad distribution of this combined program through U.S. “In addition, we believe our pilot program which includes our proBEAT ™ non-invasive glucose sensor ushers in a new era in the development of life management tools that have been scientifically validated and utilize a personalized coaching method that combines a digital platform with data from a unique non-invasive device. Faz Chowdhury, Nemaura’s Chief Executive Officer.
“We believe that the BEAT ®diabetes app offers a significant new path toward better lifestyle management with the overall aim of providing a better tool for improved management and potential reversal of Type 2 diabetes,” commented Dr. proBEAT ™ is a flexible wear patch, which provides feedback and actionable insights to users to better understand how diet and lifestyle adjustments might impact blood glucose fluctuations, empowering its users with knowledge that can lead to smarter decisions and improved overall health and well-being. The Company is also beginning pilot programs that include its proprietary proBEAT ™ monitor, a non-invasive, daily-wear glucose monitoring patch, synced with the BEAT ®diabetes program. The program is based on an in-clinic program originally developed and validated at the Joslin Diabetes Center. As new information is processed, Lena offers feedback and encouragement as well as helpful ideas to help users not only improve their health, but potentially reverse Type 2 diabetes. It also features continuous one-on-one support through its AI avatar, Lena, who learns about user habits and regularly becomes more familiar with each user. The BEATdiabetes app, which is publicly available through the Google Play store and Apple’s app store provides predictive information that supplies the user suggestions such as smart eating choices, exercise and other potential lifestyle changes over the long term based on information provided by the user.
(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of its BEAT ®diabetes app on the GooglePlay and iOS platforms. Loughborough, England, Ap(GLOBE NEWSWIRE) - Nemaura Medical, Inc.
0 kommentar(er)
